Compare BARK & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BARK | NTHI |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.7M | 109.5M |
| IPO Year | 2020 | 2023 |
| Metric | BARK | NTHI |
|---|---|---|
| Price | $10.67 | $4.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $37.50 | $15.00 |
| AVG Volume (30 Days) | 51.4K | ★ 200.7K |
| Earning Date | 06-03-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $394,843,000.00 | $39,990.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.43 | N/A |
| P/E Ratio | $126.25 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.50 | $3.01 |
| 52 Week High | $11.32 | $12.99 |
| Indicator | BARK | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 58.62 | 58.50 |
| Support Level | $8.49 | $4.18 |
| Resistance Level | $10.94 | $5.78 |
| Average True Range (ATR) | 0.63 | 0.63 |
| MACD | 0.06 | 0.22 |
| Stochastic Oscillator | 75.84 | 60.97 |
BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.